Literature DB >> 18930572

Eye movement dysfunction in first-degree relatives of patients with schizophrenia: a meta-analytic evaluation of candidate endophenotypes.

Monica E Calkins1, William G Iacono, Deniz S Ones.   

Abstract

Several forms of eye movement dysfunction (EMD) are regarded as promising candidate endophenotypes of schizophrenia. Discrepancies in individual study results have led to inconsistent conclusions regarding particular aspects of EMD in relatives of schizophrenia patients. To quantitatively evaluate and compare the candidacy of smooth pursuit, saccade and fixation deficits in first-degree biological relatives, we conducted a set of meta-analytic investigations. Among 18 measures of EMD, memory-guided saccade accuracy and error rate, global smooth pursuit dysfunction, intrusive saccades during fixation, antisaccade error rate and smooth pursuit closed-loop gain emerged as best differentiating relatives from controls (standardized mean differences ranged from .46 to .66), with no significant differences among these measures. Anticipatory saccades, but no other smooth pursuit component measures were also increased in relatives. Visually-guided reflexive saccades were largely normal. Moderator analyses examining design characteristics revealed few variables affecting the magnitude of the meta-analytically observed effects. Moderate effect sizes of relatives v. controls in selective aspects of EMD supports their endophenotype potential. Future work should focus on facilitating endophenotype utility through attention to heterogeneity of EMD performance, relationships among forms of EMD, and application in molecular genetics studies.

Entities:  

Mesh:

Year:  2008        PMID: 18930572      PMCID: PMC4654966          DOI: 10.1016/j.bandc.2008.09.001

Source DB:  PubMed          Journal:  Brain Cogn        ISSN: 0278-2626            Impact factor:   2.310


  217 in total

Review 1.  Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia.

Authors:  A Bertolino; G Esposito; J H Callicott; V S Mattay; J D Van Horn; J A Frank; K F Berman; D R Weinberger
Journal:  Am J Psychiatry       Date:  2000-01       Impact factor: 18.112

2.  Saccadic disinhibition in schizophrenia patients and their first-degree biological relatives. A parametric study of the effects of increasing inhibitory load.

Authors:  C E Curtis; M E Calkins; W G Iacono
Journal:  Exp Brain Res       Date:  2001-03       Impact factor: 1.972

Review 3.  Genetics of the risk for alcoholism.

Authors:  M A Schuckit
Journal:  Am J Addict       Date:  2000

4.  Neuroscience. Deconstructing schizophrenia.

Authors:  Constance Holden
Journal:  Science       Date:  2003-01-17       Impact factor: 47.728

5.  A multivariate electrophysiological endophenotype, from a unitary cohort, shows greater research utility than any single feature in the Western Australian family study of schizophrenia.

Authors:  Gregory W Price; Patricia T Michie; Julie Johnston; Hamish Innes-Brown; Aaron Kent; Peter Clissa; Assen V Jablensky
Journal:  Biol Psychiatry       Date:  2005-12-20       Impact factor: 13.382

6.  Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia.

Authors:  Sherry Leonard; Judith Gault; Jan Hopkins; Judith Logel; Ruby Vianzon; Margaret Short; Carla Drebing; Ralph Berger; Diana Venn; Pinkhas Sirota; Gary Zerbe; Ann Olincy; Randal G Ross; Lawrence E Adler; Robert Freedman
Journal:  Arch Gen Psychiatry       Date:  2002-12

7.  Recent studies of psychophysiology in schizophrenia.

Authors:  H E Spohn; T Patterson
Journal:  Schizophr Bull       Date:  1979       Impact factor: 9.306

8.  Saccadic distractibility in first-episode schizophrenia.

Authors:  S B Hutton; E M Joyce; T R E Barnes; C Kennard
Journal:  Neuropsychologia       Date:  2002       Impact factor: 3.139

9.  Components of the smooth pursuit function in deficit and nondeficit schizophrenia.

Authors:  L Elliot Hong; Matthew T Avila; Helene Adami; Amie Elliot; Gunvant K Thaker
Journal:  Schizophr Res       Date:  2003-09-01       Impact factor: 4.939

10.  Smooth pursuit performance in patients with affective disorders or schizophrenia and normal controls: analysis with specific oculomotor measures, RMS error and qualitative ratings.

Authors:  L Friedman; J A Jesberger; L J Siever; P Thompson; R Mohs; H Y Meltzer
Journal:  Psychol Med       Date:  1995-03       Impact factor: 7.723

View more
  37 in total

1.  Antisaccade performance in schizophrenia patients, their first-degree biological relatives, and community comparison subjects: data from the COGS study.

Authors:  Allen D Radant; Dorcas J Dobie; Monica E Calkins; Ann Olincy; David L Braff; Kristin S Cadenhead; Robert Freedman; Michael F Green; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Gregory A Light; Sean P Meichle; Steve P Millard; Jim Mintz; Keith H Nuechterlein; Nicholas J Schork; Larry J Seidman; Larry J Siever; Jeremy M Silverman; William S Stone; Neal R Swerdlow; Ming T Tsuang; Bruce I Turetsky; Debby W Tsuang
Journal:  Psychophysiology       Date:  2010-04-05       Impact factor: 4.016

2.  Association of variants in DRD2 and GRM3 with motor and cognitive function in first-episode psychosis.

Authors:  Rebekka Lencer; Jeffrey R Bishop; Margret S H Harris; James L Reilly; Shitalben Patel; Rick Kittles; Konasale M Prasad; Vishwajit L Nimgaonkar; Matcheri S Keshavan; John A Sweeney
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-10-25       Impact factor: 5.270

3.  Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.

Authors:  L Elliot Hong; Gunvant K Thaker; Robert P McMahon; Ann Summerfelt; Jill Rachbeisel; Rebecca L Fuller; Ikwunga Wonodi; Robert W Buchanan; Carol Myers; Stephen J Heishman; Jeff Yang; Adrienne Nye
Journal:  Arch Gen Psychiatry       Date:  2011-08-01

Review 4.  Eye tracking dysfunction in schizophrenia: characterization and pathophysiology.

Authors:  Deborah L Levy; Anne B Sereno; Diane C Gooding; Gilllian A O'Driscoll
Journal:  Curr Top Behav Neurosci       Date:  2010

Review 5.  Atypical scanpaths in schizophrenia: evidence of a trait- or state-dependent phenomenon?

Authors:  Sara A Beedie; Philip J Benson; David M St Clair
Journal:  J Psychiatry Neurosci       Date:  2011-05       Impact factor: 6.186

6.  Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy.

Authors:  Anne Schmechtig; Jane Lees; Lois Grayson; Kevin J Craig; Rukiya Dadhiwala; Gerard R Dawson; J F William Deakin; Colin T Dourish; Ivan Koychev; Katrina McMullen; Ellen M Migo; Charlotte Perry; Lawrence Wilkinson; Robin Morris; Steve C R Williams; Ulrich Ettinger
Journal:  Psychopharmacology (Berl)       Date:  2013-02-22       Impact factor: 4.530

7.  Pursuit eye movements as an intermediate phenotype across psychotic disorders: Evidence from the B-SNIP study.

Authors:  Rebekka Lencer; Andreas Sprenger; James L Reilly; Jennifer E McDowell; Leah H Rubin; Judith A Badner; Matcheri S Keshavan; Godfrey D Pearlson; Carol A Tamminga; Elliot S Gershon; Brett A Clementz; John A Sweeney
Journal:  Schizophr Res       Date:  2015-10-23       Impact factor: 4.939

8.  Effects of ketamine on brain function during response inhibition.

Authors:  M Steffens; C Neumann; A-M Kasparbauer; B Becker; B Weber; M A Mehta; R Hurlemann; U Ettinger
Journal:  Psychopharmacology (Berl)       Date:  2018-10-24       Impact factor: 4.530

9.  Schizophrenia-related neuregulin-1 single-nucleotide polymorphisms lead to deficient smooth eye pursuit in a large sample of young men.

Authors:  Nikolaos Smyrnis; Emmanouil Kattoulas; Nicholas C Stefanis; Dimitrios Avramopoulos; Costas N Stefanis; Ioannis Evdokimidis
Journal:  Schizophr Bull       Date:  2009-12-04       Impact factor: 9.306

10.  SPEM dysfunction and general schizotypy as measured by the SSQ: a controlled study.

Authors:  Dirk van Kampen; Jan Berend Deijen
Journal:  BMC Neurol       Date:  2009-06-29       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.